ALDX
Aldeyra Therapeutics, Inc.
Key Financials
Net Income
$-33846661
↑ 39.4%
Total Assets
$72.1M
↓ 31.1%
Operating Income
$-35265206
↑ 41.3%
Total Liabilities
$27.8M
↓ 17.2%
EPS (Diluted)
$-0.56
↑ 40.4%
Cash & Equivalents
$70.0M
↑ 28.5%
Long-term Debt
$15.3M
0.0%
Operating Cash Flow
$-33345682.00
↑ 22.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/29/2026 | View on SEC |
| SCHEDULE 13G | 8/12/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| 8-K | 7/30/2026 | View on SEC |
| SCHEDULE 13G/A | 7/27/2026 | View on SEC |
| 8-K | 7/15/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ALDX |
| Company Name | Aldeyra Therapeutics, Inc. |
| CIK | 1341235 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 781-761-4904 |